DEF 14A: Cryo-Cell International Sets Date for 2024 Annual Stockholder Meeting

Cryo-Cell International will hold its annual stockholder meeting on October 29, 2024, to elect directors, ratify the appointment of auditors, and conduct an advisory vote on executive compensation.

Summary

• Cryo-Cell International, Inc. will hold its 2024 Annual Meeting of Stockholders on October 29, 2024, at 11:00 a.m. local time, at its offices in Oldsmar, Florida.
• The meeting will address the election of four directors, ratification of Wipfli LLP as the independent registered public accountants for the fiscal year ending November 30, 2024, and a non-binding advisory resolution on executive compensation.
• The record date for determining stockholders entitled to vote at the Annual Meeting was September 20, 2024.
• Stockholders are encouraged to complete and return the proxy card or submit a proxy via the Internet or telephone.
• As of the record date, there were 8,062,159 shares outstanding.
• The Board recommends voting for the director nominees and for Proposals 2, 3, and 4.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions, but does not express strong positive or negative sentiment.

Positives

• The Audit Committee is comprised of independent members and has an Audit Committee financial expert.
• The company encourages stockholders to communicate with the board of directors regarding concerns about financial statements, accounting practices, internal controls, governance practices, business ethics, or corporate conduct.
• The company provides multiple avenues for stockholders to vote, including mail, internet, and mobile voting.

Negatives

• David Portnoy serves as both Chairman of the Board and Co-Chief Executive Officer, which could present potential conflicts of interest.
• The Governance Committee charter does not cover procedures for director nominations made by the board of directors.
• The Nominating Committee does not have a charter.

Risks

• The proxy statement mentions a one-year non-competition restriction and a 12-month restriction on solicitation of employees or customers in the executive employment agreements, which could pose a risk if key executives leave the company.
• The document mentions potential conflicts of interest overseen by the Audit Committee, suggesting inherent risks in related party transactions or other financial dealings.
• The document mentions that the Compensation Committee is responsible for overseeing the management of risks relating to the Company's executive compensation plans and arrangements, suggesting inherent risks in the compensation structure.

Future Outlook

The document outlines procedures for stockholder proposals for the 2025 Annual Meeting, indicating a continuation of corporate governance processes.

Management Comments

• David Portnoy, Chairman and Co-Chief Executive Officer, urges stockholders to read the Proxy Statement and submit a proxy for their shares as soon as possible.
• The Board of Directors has an active role in overseeing management of the Company's risks.

Industry Context

This document is a standard proxy statement related to corporate governance, aligning with typical practices for publicly traded companies. It does not provide specific details to compare to industry trends or competitors.

Comparison to Industry Standards

• The structure and content of the proxy statement align with standard practices for publicly traded companies in the United States, as mandated by the Securities and Exchange Commission (SEC).
• The disclosure of executive compensation, related party transactions, and audit fees is consistent with SEC regulations and industry norms.
• The descriptions of the roles and responsibilities of the Board of Directors and its committees are typical for companies of similar size and complexity.
• The process for nominating directors and submitting stockholder proposals follows established corporate governance guidelines.

Related Party Transactions

• David Portnoy, the Company's Chairman and Co-Chief Executive Officer, is the brother of the Company's Co-Chief Executive Officer, Mark Portnoy.
• The Company's Audit Committee Chairman, Harold Berger, provides accounting services to the Company's Co-Chief Executive Officer, Mark Portnoy.

Stakeholder Impact

• Shareholders are directly impacted through their voting rights on key company decisions.
• Employees are indirectly impacted through the approval of executive compensation and the election of directors who oversee company strategy.
• The outcome of the meeting could influence investor confidence and the company's market valuation.

Next Steps

• Stockholders are to review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on October 29, 2024.
• The Board of Directors will consider the outcome of the advisory vote on executive compensation when making future decisions.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, executive compensation, audit committee, Wipfli LLP, governance, Cryo-Cell International